
Please try another search
Axcella Health Inc. is a clinical-stage biotechnology company focused on a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs). The Company’s product candidates are comprised of multiple EMMs that are engineered in distinct combinations and ratios with the goal of simultaneously impacting multiple biological pathways. AXA1665 is being developed as a product candidate for the reduction in risk of overt hepatic encephalopathy (OHE) recurrence in adult patients with liver cirrhosis. Its AXA1125 AXA1125 is being developed as an oral product candidate for the treatment of non-alcoholic steatohepatitis (NASH). The Company’s pipeline includes lead therapeutic candidates for the treatment of NASH, for the treatment of long COVID (also known as Post COVID-19 Condition and Post-Acute Sequelae of COVID-19, or PASC) associated fatigue, and for the reduction in risk of recurrent OHE.
Name | Age | Since | Title |
---|---|---|---|
Martin Hendrix | 54 | 2022 | Independent Director |
Gary P. Pisano | 60 | 2011 | Independent Director |
William R. Hinshaw | 53 | 2018 | President, CEO & Director |
William D. Baird | 50 | 2018 | Independent Director |
Catherine Angell Sohn | 69 | 2019 | Independent Director |
Robert L. Rosiello | 64 | 2022 | Independent Chairman of the Board |
Paul J. Sekhri | 64 | 2022 | Independent Director |
Cristina M. Rondinone | 61 | 2018 | Independent Director |
Torben Straight Nissen | - | 2022 | Independent Director |
Michael Rosenblatt | 74 | 2022 | Scientific Advisor & Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review